The High-Throughput Screening Core allows the rapid identification of biologically active chemical scaffolds from libraries containing several thousand discrete chemicals, and potentially containing naturally occurring ones obtained from natural sources such as plants. MSKCC has implemented the creation of a state of the art high throughput screening core facility with modern robotics, custom built screening data management databases for storing and querying data, and setting up strategic collaborations for the supply chemicals and to provide expertise in medicinal chemistry optimization. The facility contains a custom built six meter linear track robotic platform equipped with plate hotels, incubators for cell based assays, bulk liquid dispensers (Multidrops), 384/1536 liquid handlers (Apricot Designs TPS), a Perkin Elmer MicroBeta counter, two Perkin Elmer Victors multi-detection plates readers, two Molecular Device absorbance scanners, and one Amersham Multi-detection imager. Screening data acquisition and management is handled through custom built software named ORIS, which is composed of a chemical registration and inventory function together with an automated data loader for acquisition, analysis and screen data publishing. The compound library will grow to up to 500,000 discrete chemicals from selected commercial vendors and will also contain a wide variety of natural products, some purified and others in extract mixtures pending screening and dereplication to identify and purify the active product(s). The impact of such an infrastructure on the ongoing cancer research will be in the following areas: 1) Chemical cancer biology to discover novel control mechanisms to help further elucidate known or discover novel cancer pathways including control junctions, 2) Novel chemical scaffolds for use as radiotracers for biochemical and metabolic studies in vivo and for use in cancer diagnostics, and 3) the classical drug discovery process in which in vitro and/or cell based targets are screened and the resulting chemical hits are subjected to secondary and high content screens, in order to further optimize their chemical structures and their drug properties, and to show some efficacy against the specific cancer with little or no side effects, making them good drug candidates for the clinic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-46
Application #
8243721
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-01-01
Budget End
2011-12-31
Support Year
46
Fiscal Year
2011
Total Cost
$629,732
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Assel, Melissa J; Li, Fan; Wang, Ying et al. (2018) Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration: Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study. Ophthalmology 125:391-397
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Yeung, K Simon; Hernandez, Marisol; Mao, Jun J et al. (2018) Herbal medicine for depression and anxiety: A systematic review with assessment of potential psycho-oncologic relevance. Phytother Res 32:865-891
Audenet, Fran├žois; Vertosick, Emily A; Fine, Samson W et al. (2018) Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer. J Urol 199:961-968
Petrovic, Ivana; Rosen, Evan B; Matros, Evan et al. (2018) Oral rehabilitation of the cancer patient: A formidable challenge. J Surg Oncol 117:1729-1735
Balakrishnan, Mridula; Baylies, Mary K (2018) Myonuclear Positioning and Aneurysms Are LINC'd by Ariande. Dev Cell 45:149-150
McKnight, Brooke N; Kuda-Wedagedara, Akhila N W; Sevak, Kuntal K et al. (2018) Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab). Sci Rep 8:9043
Thor, Maria; Jackson, Andrew; Zelefsky, Michael J et al. (2018) Inter-institutional analysis demonstrates the importance of lower than previously anticipated dose regions to prevent late rectal bleeding following prostate radiotherapy. Radiother Oncol 127:88-95
Wiener, Lori; Rosenberg, Abby R; Lichtenthal, Wendy G et al. (2018) Personalized and yet standardized: An informed approach to the integration of bereavement care in pediatric oncology settings. Palliat Support Care 16:706-711
Damaskos, Penny; Amaya, Beau; Gordon, RuthAnn et al. (2018) Intersectionality and the LGBT Cancer Patient. Semin Oncol Nurs 34:30-36

Showing the most recent 10 out of 8799 publications